机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou/CN,广东省人民医院[2]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN, [3]Shanghai Pulmonary Hospital &thoracic Cancer Institute, Tongji University School of Medicine, Shanghai/CN, [4]Daping Hospital, Army Medical University, Chongqing/CN, 5Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou/CN广东省中医院
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou/CN,
推荐引用方式(GB/T 7714)：
Lu C.,Zhou Z.,Zheng D.,et al.Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/in trans-C797S Mutations After Resistance to Osimertinib[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(3):S594-S594.doi:10.1016/j.jtho.2021.01.1076.
APA：
Lu, C.,Zhou, Z.,Zheng, D.,He, Y.,Li, Y....&Zhou, Q..(2021).Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/in trans-C797S Mutations After Resistance to Osimertinib.JOURNAL OF THORACIC ONCOLOGY,16,(3)
MLA：
Lu, C.,et al."Clinical Outcomes of Lung Cancer Patients Who Acquired EGFR T790M/in trans-C797S Mutations After Resistance to Osimertinib".JOURNAL OF THORACIC ONCOLOGY 16..3(2021):S594-S594
医学